Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · IEX Real-Time Price · USD
16.55
+0.21 (1.29%)
At close: Jul 2, 2024, 4:00 PM
16.59
+0.04 (0.24%)
After-hours: Jul 2, 2024, 7:51 PM EDT
Teva Pharmaceutical Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Teva Pharmaceutical stock have an average target of 17, with a low estimate of 11 and a high estimate of 23. The average target predicts an increase of 2.72% from the current stock price of 16.55.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Teva Pharmaceutical stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 3 | 3 | 3 | 2 | 2 |
| Hold | 2 | 2 | 3 | 3 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 10 | 10 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Maintains $19 → $23 | Strong Buy | Maintains | $19 → $23 | +38.97% | Jun 27, 2024 |
| Barclays | Barclays | Buy Maintains $20 → $21 | Buy | Maintains | $20 → $21 | +26.89% | Jun 5, 2024 |
| B of A Securities | B of A Securities | Strong Buy Maintains $18 → $21 | Strong Buy | Maintains | $18 → $21 | +26.89% | May 30, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $19 → $20 | Buy | Reiterates | $19 → $20 | +20.85% | May 13, 2024 |
| Barclays | Barclays | Buy Maintains $17 → $20 | Buy | Maintains | $17 → $20 | +20.85% | May 9, 2024 |
Financial Forecast
Revenue This Year
16.27B
from 15.85B
Increased by 2.64%
Revenue Next Year
16.87B
from 16.27B
Increased by 3.71%
EPS This Year
2.46
from -0.50
EPS Next Year
2.80
from 2.46
Increased by 13.68%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 16.9B | 17.9B | 18.2B |
| Avg | 16.3B | 16.9B | 17.0B |
| Low | 15.6B | 15.9B | 15.7B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 6.7% | 9.8% | 7.6% |
| Avg | 2.6% | 3.7% | 0.8% |
| Low | -1.8% | -2.2% | -7.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 2.63 | 3.08 | 3.03 |
| Avg | 2.46 | 2.80 | 2.87 |
| Low | 2.26 | 2.59 | 2.64 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | 25.0% | 8.5% |
| Avg | - | 13.7% | 2.6% |
| Low | - | 5.1% | -5.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.